Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11224282 | 0.95 | ESR1 (0.47) | ESR1CYP19A1ESR2TYRTAAR1 | |
| SCHEMBL9921244 | 0.89 | TAAR1 (0.46) | ESR1CYP19A1ESR2TAAR1ADRA1A | |
| SCHEMBL19304105 | 0.87 | CHRM2 (0.54) | ESR1CYP19A1ESR2TAAR1ADRA1A | |
| SCHEMBL23575258 | 0.85 | ESR1 (0.47) | ESR1CYP19A1ESR2TYRTAAR1 | |
| SCHEMBL30250416 | 0.85 | ESR1 (0.47) | ESR1CYP19A1ESR2TYRTAAR1 | |
| SCHEMBL27633878 | 0.84 | ESR1 (0.69) | ESR1CYP19A1ESR2TYRPOLB | |
| SCHEMBL8132364 | 0.82 | POLB (0.46) | TAAR1ADRA1AKDM1AMAOAMAOB | |
| SCHEMBL9417780 | 0.81 | APLNR (0.58) | TAAR1ADRA1A | |
| SCHEMBL16772275 | 0.81 | KMT2A (0.52) | ESR1CYP19A1ESR2TYRTAAR1 | |
| SCHEMBL18402965 | 0.81 | MTNR1A (0.48) | ESR1CYP19A1ESR2TAAR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3271333-B1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | ESR1 614/4885CYP19A1 1064/4885ESR2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.